Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
Basilea (SIX: BSLN): another Cresemba milestone payment
Published by Arron Aatkar, PhD

Basilea Pharmaceutica has announced that the continued strong sales of Cresemba (isavuconazole, the copmany’s lead antifungal therapy)has triggered the second US$2.5m payment of the year. This milestone payment comes from Pfizer, based on the license agreement between the companies which covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific Region.

Cresemba is marketed in over 70 countries. According to the latest available data, total global in-market sales of Cresemba in the 12-month period between January and December 2024 amounted to US$562m, a 19% growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free